Research Article
Pamidronate Disodium for Palliative Therapy of Feline Bone-Invasive Tumors
Table 4
Potential treatment factors contributing to azotemia.
| | Cat | Azotemia relative to initial pamidronate | Potential nephrotoxic factors | | Number of pamidronate treatments | Cumulative pamidronate mg/kg | Concurrent NSAID | Sedation or chemotherapy
concurrent (C) with or prior (P) to azotemia |
| | 1 | 2 weeks post | 1 | 1 | Meloxicam | Sedation (P) | | 2 | 20 weeks post | 3 | 3 | Meloxicam | Sedation (P) | | 3 | 6 weeks post | 1 | 1.5 | Meloxicam | Sedation (P) | | 4 | None | 4 | 8 | Piroxicam | Sedation, carboplatin, mitoxantrone (P) | | 5 | None | 1 | 1 | Piroxicam | Carboplatin (C) | | 6 | None | 1 | 1.5 | None | Sedation, mitoxantrone (C) | | 7 | Stable CRF | 1 | 1 | None | Sedation (P) | | 8 | None | 2 | 2.8 | Meloxicam | Mitoxantrone, carboplatin, gemcitabine, Palladia (C) |
|
|
